Internal Reference Number: FOI_8953
Date Request Received: 08/10/2025 00:00:00
Date Request Replied To: 21/10/2025 00:00:00
This response was sent via: By Email
Request Summary: Lung Cancer
Request Category: Researcher
| Question Number 1: I am analysing the treatment of lung cancer and would greatly appreciate it if you could answer the following question: How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) • Amivantamab Monotherapy • Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) • Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel • Atezolizumab monotherapy (subcutaneous injection only) • Dabrafenib + Trametinib • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin • Durvalumab • Gemcitabine • Nintedanib + Docetaxel • Nivolumab • Osimertinib • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) • Paclitaxel • Pembrolizumab Monotherapy • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) • Pemetrexed + Platinum (Carboplatin/Cisplatin) • RET Inhibitors (Pralsetinib, Selpercatinib) • Sotorasib • Tepotinib • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin • Other active systemic anti-cancer therapy • Palliative care only • Amivantamab with carboplatin and pemetrexed • Cemiplimab with platinum-based chemotherapy • Adagrasib • Datopotamab deruxtecan • Amivantamab with lazertinib | |
| Answer To Question 1: ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) 12 • Amivantamab Monotherapy 0 • Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) <5 • Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel <5 • Atezolizumab monotherapy (subcutaneous injection only) <5 • Dabrafenib + Trametinib <5 • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 0 • Durvalumab 5 • Gemcitabine 0 • Nintedanib + Docetaxel <5 • Nivolumab 0 • Osimertinib 17 • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) <5 • Paclitaxel 0 • Pembrolizumab Monotherapy 6 • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) <5 • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 17 • Pemetrexed + Platinum (Carboplatin/Cisplatin) <5 • RET Inhibitors (Pralsetinib, Selpercatinib) 0 • Sotorasib <5 • Tepotinib <5 • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin <5 • Other active systemic anti-cancer therapy <5 • Palliative care only unable to answer • Amivantamab with carboplatin and pemetrexed 0 • Cemiplimab with platinum-based chemotherapy 0 • Adagrasib 0 • Datopotamab deruxtecan 0 • Amivantamab with Lazertinib 0 | |
| Question Number 2: . Does your trust participate in any clinical trials for Non-Small Cell Lung Cancer? If so, please provide the name of each trial, and the number of patients taking part. | |
| Answer To Question 2: The Trust currently do not have any clinical trials for lung cancer that are open to recruitment. However, we have expressed interest to sponsors in a few studies for which we are yet to receive feedback. Previously, we have participated in the ET Trial and TACTIC. | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
